Market Place
Sourcing Support
Dr. Reddy’s receives positive opinion from EMA for Rituximab biosimilar
29 Jul 2024 //
PRESS RELEASE
Inconsistent survival data dent Roche`s Columvi win in 2L DLBCL
17 Jun 2024 //
FIERCE PHARMA
Pfizer reports positive results from Echelon-3 study
17 Jun 2024 //
INDIANPHARMAPOST
Roche`s Columvi Extends Large B-Cell Lymphoma Survival
15 Jun 2024 //
GLOBENEWSWIRE
Genentech`s Columvi Extends Survival In R R DLBCL
14 Jun 2024 //
BUSINESSWIRE
Enterome updates clinical data from ongoing EONHL1-20/SIDNEY trial EO2463
27 May 2024 //
PHARMABIZ
Genentech’s Columvi Meets Primary Endpoint Ref. Diffuse Large B-Cell Lymphoma
15 Apr 2024 //
PRESS RELEASE
PolTREG identifies promising efficacy biomarker for Type-1 diabetes in patients
04 Apr 2024 //
GLOBENEWSWIRE
Pfizer`s blood cancer therapy Adcetris succeeds in late-stage trial
13 Mar 2024 //
PRESS RELEASE
Pfizer`s Ruxience (rituximab) Receives Approval in Europe
15 Dec 2023 //
EMA
ADC Therapeutics Announces Initial Results from Phase 2 Evaluating ZYNLONTA
12 Dec 2023 //
GLOBENEWSWIRE
Pfizer Inc`s Biologic Ruxience (Rituximab) Receives Approval in the U.S.
16 Oct 2023 //
FDA
Artiva Announces FDA Clearance of IND for AlloNK® Cell Therapy Candidate
16 Aug 2023 //
BUSINESSWIRE
Obesity drugs don`t make WHO`s essential list, but Ebola, MS drugs added
27 Jul 2023 //
REUTERS
Dr Reddy`s application for biosimilar candidate accepted for review by USFDA
13 Jul 2023 //
ECONOMIC TIMES
ADC Therapeutics pauses enrollment in cancer drug trial after patient deaths
12 Jul 2023 //
REUTERS
Roche to present new data in blood cancers and solid tumours at ASCO 2023
26 May 2023 //
GLOBENEWSWIRE
Artiva boasts early NK cell therapy results, giving lifeline to partner Affimed
26 May 2023 //
ENDPTS
FDA adcomm votes 11-2 to expand Roche`s Polivy label in DLBCL
10 Mar 2023 //
ENDPTS
Dr Reddy`s completes clinical studies of proposed rituximab biosimilar candidate
20 Jan 2023 //
ECONOMIC TIMES
Genentech Presents Data for Polivy at ASH 2022
11 Dec 2022 //
BUSINESSWIRE
NICE signs off on BeiGene`s Brukinsa for blood cancer disorder
20 Sep 2022 //
FIERCEPHARMA
Genor Biopharma: Launch Of Phase I/II Clinical Trial Of GB261 In China
09 Sep 2022 //
FIRSTWORLDPHARMA
FDA accepts supplemental BLA for Roche’s Polivy combo
17 Aug 2022 //
THEPHARMALETTER
Genentech lymphoma treatment gets FDA approval
16 Aug 2022 //
LABIOTECH
Overland ADCT BioPharma Begins Dosing in China with ZYNLONTA in PIII trial
11 Jul 2022 //
BUSINESSWIRE
FDA Approves Riabni For Adults With Moderate To Severe Rheumatoid Arthritis
06 Jun 2022 //
PRNEWSWIRE
EC approves Roche’s Polivy combination in previously untreated diffuse LBCL
26 May 2022 //
EXPRESS PHARMA
Fresenius agrees two acquisitions to bolster Kabi drugs unit
01 Apr 2022 //
REUTERS
Celltrion`s Biologic Truxima (Rituximab-abbs) Receives Approval in the U.S.
04 Feb 2022 //
FDA
VFMCRP receives EU approval for Tavneos in ANCA-associated vasculitis
19 Jan 2022 //
BUSINESSWIRE
Nordic Nanovector Provides update on PARADIGME; Phase 2b Trial with Betalutin
07 Jan 2022 //
PRNEWSWIRE
Zenyaku Kogyo gets Japanese approval for anti-CD20 mAb, Rituxan
24 Dec 2021 //
PHARMABIZ
Genentech`s Biologic Rituxan (Rituximab) Receives Approval in the U.S.
17 Dec 2021 //
FDA
Progression-Free Survival Boost Noted With Polatuzumab Vedotin Plus R-CHP
17 Dec 2021 //
CANCERNETWORK
I-Mab Presents Interim Clinical Data of Lemzoparlimab + Rituximab in NHL
14 Dec 2021 //
PRNEWSWIRE
Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study
12 Dec 2021 //
BUSINESSWIRE
BeiGene Presents Results from SEQUOIA Trial of BRUKINSA in CLL
12 Dec 2021 //
BUSINESSWIRE
MorphoSys, Incyte Show Additional Real-World Data from RE-MIND2 Study
11 Dec 2021 //
BUSINESSWIRE
I-Mab to Hold Investor Call for Clinical Data of Lemzoparlimab + Rituximab
09 Dec 2021 //
PRNEWSWIRE
Genentech`s Biologic Rituxan (Rituximab) gets Approval in the U.S.
02 Dec 2021 //
FDA
New Analysis Published in MS Supports the Efficacy of UPLIZNA
22 Nov 2021 //
BUSINESSWIRE
Biodesix Announces Publication Highlighting Interim Data from the INSIGHT Study
18 Nov 2021 //
BUSINESSWIRE
Celltrion’s Truxima posts 46 percent market share in major European countries
13 Nov 2021 //
NEWSNOW
EMA CHMP Gives Positive Recommendation for Tavneos in ANCA Vasculitis
12 Nov 2021 //
GLOBENEWSWIRE
I-Mab to Present Clinical Data of Lemzoparlimab in Combination with Rituximab
04 Nov 2021 //
PRNEWSWIRE
BeiGene to Present Clinical Data on BRUKINSA in Chronic Lymphocytic Leukemia
04 Nov 2021 //
BUSINESSWIRE
Immunocompromised patients using rituximab could benefit from booster vaccine
02 Nov 2021 //
PRNEWSWIRE
Zenyaku Kogyo receives Japanese nod for Rituxan in systemic sclerosis
28 Sep 2021 //
PHARMABIZ
Anti-CD20 Monoclonal Antibody Rituxan Approved for Systemic Sclerosis
27 Sep 2021 //
PRESS RELEASE
Chinese antibody player chases Hong Kong IPO
19 Jul 2021 //
ENDPTS
Naratuximab Emtansine Plus Rituximab Shows Promise for Relapsed/Refractory DLBCL
18 Jun 2021 //
CANCERTHERAPYADVISOR
Genentech`s Biological Rituximab; Hyaluronidase Receives Approval In US
15 Jun 2021 //
FDA
Celltrion presents first real-world data at AEH 2021 for its drug Truxima
14 Jun 2021 //
BUSINESSWIRE
CBMG` Novel CD19/CD20 Bi-specific CAR-T Cell Product Shows Promising Results
10 Jun 2021 //
PRNEWSWIRE
CBMG` Novel Anti-CD20 CAR-T Cell Therapy Shows Promising Safety and Efficacy
10 Jun 2021 //
PRNEWSWIRE
Nordic Nanovector Announces Update from Archer-1 Ph1b Trial of Betalutin®
25 May 2021 //
PRNEWSWIRE
Health Canada Approves IMBRUVICA®* (ibrutinib) Plus Rituximab
13 Jan 2021 //
NEWSWIRE
Amgen`s Riabni (rituximab-arrx) Receives Supplemental Approval In US
21 Dec 2020 //
FDA
NMPA Has Accepted The NDA Of HLX01 (Rituximab Injection)
18 Dec 2020 //
BIOSIMILARDEVELOPMENT
